VR 588

Drug Profile

VR 588

Alternative Names: VR588

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vectura
  • Developer Imperial College of Science, Technology and Medicine; Vectura
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TRPV1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Asthma
  • Preclinical Inflammation

Most Recent Events

  • 04 Jan 2018 VR 588 is available for licensing as of 04 Jan 2018. www.vectura.com
  • 23 Nov 2016 Vectura plans a phase I/IIa trial of VR 588 in Respiratory tract disorders
  • 19 Oct 2016 Vectura completes a phase I trial in Asthma in United Kingdom (NCT02740049)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top